CD274 and hepatocellular carcinoma: Durvalumab, a fully human anti-PD-L1 mAb, has shown an acceptable safety profile and promising antitumor activity for patients with advanced HCC pre-treated with sorafenib in a multicenter, open-label, single group assignment phase I/II study (NCT01693562, Table 1) (50).